BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 16721364)

  • 1. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients.
    Streit S; Mestel DS; Schmidt M; Ullrich A; Berking C
    Br J Cancer; 2006 Jun; 94(12):1879-86. PubMed ID: 16721364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
    Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
    J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression.
    Ye Y; Shi Y; Zhou Y; Du C; Wang C; Zhan H; Zheng B; Cao X; Sun MH; Fu H
    Ann Surg Oncol; 2010 Dec; 17(12):3354-61. PubMed ID: 20844967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas.
    Wimmer E; Ihrler S; Gires O; Streit S; Issing W; Bergmann C
    World J Clin Oncol; 2019 Mar; 10(3):136-148. PubMed ID: 30949443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma.
    da Costa Andrade VC; Parise O; Hors CP; de Melo Martins PC; Silva AP; Garicochea B
    Exp Mol Pathol; 2007 Feb; 82(1):53-7. PubMed ID: 17084840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition.
    Ye Y; Li J; Jiang D; Li J; Xiao C; Li Y; Han C; Zhao C
    Cancer Res Treat; 2020 Oct; 52(4):1162-1177. PubMed ID: 32599983
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Cho SH; Hong CS; Kim HN; Shin MH; Kim KR; Shim HJ; Hwang JE; Bae WK; Chung IJ
    Cancer Res Treat; 2017 Jul; 49(3):766-777. PubMed ID: 27857023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma.
    Streit S; Bange J; Fichtner A; Ihrler S; Issing W; Ullrich A
    Int J Cancer; 2004 Aug; 111(2):213-7. PubMed ID: 15197773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Polymorphism in the FGFR4 Gene Is Associated With Risk of Neuroblastoma and Altered Receptor Degradation.
    Whittle SB; Reyes S; Du M; Gireud M; Zhang L; Woodfield SE; Ittmann M; Scheurer ME; Bean AJ; Zage PE
    J Pediatr Hematol Oncol; 2016 Mar; 38(2):131-8. PubMed ID: 26840079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gender-Specific Association Between FGFR4 Gly388Arg Gene Variants and Hypertension.
    Al-Daghri NM; Mohammed AK; Al-Attas OS; Draz HM; Alokail MS
    Genet Test Mol Biomarkers; 2017 Jul; 21(7):422-427. PubMed ID: 28650667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung.
    Falvella FS; Frullanti E; Galvan A; Spinola M; Noci S; De Cecco L; Nosotti M; Santambrogio L; Incarbone M; Alloisio M; Calabrò E; Pastorino U; Skaug V; Haugen A; Taioli E; Dragani TA
    Int J Cancer; 2009 Jun; 124(12):2880-5. PubMed ID: 19296538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy.
    Shim HJ; Shin MH; Kim HN; Kim JH; Hwang JE; Bae WK; Chung IJ; Cho SH
    Cancer Res Treat; 2016 Jan; 48(1):71-9. PubMed ID: 25989802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer.
    Marmé F; Werft W; Benner A; Burwinkel B; Sinn P; Sohn C; Lichter P; Hahn M; Schneeweiss A
    Ann Oncol; 2010 Aug; 21(8):1636-1642. PubMed ID: 20147743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer.
    Sahadevan K; Darby S; Leung HY; Mathers ME; Robson CN; Gnanapragasam VJ
    J Pathol; 2007 Sep; 213(1):82-90. PubMed ID: 17607666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer.
    Sasaki H; Okuda K; Kawano O; Yukiue H; Yano M; Fujii Y
    Oncol Rep; 2008 Nov; 20(5):1125-30. PubMed ID: 18949411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is FGFR4 Gly388Arg missense variant a suitable prognostic marker in neuroblastoma?
    Katarzyna S
    J Cancer Res Ther; 2023; 19(2):355-358. PubMed ID: 37006072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGFR4 profile as a prognostic marker in squamous cell carcinoma of the mouth and oropharynx.
    Dutra RL; de Carvalho MB; Dos Santos M; Mercante AM; Gazito D; de Cicco R; Group G; Tajara EH; Louro ID; da Silva AM
    PLoS One; 2012; 7(11):e50747. PubMed ID: 23226373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
    Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
    J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression.
    Wang J; Stockton DW; Ittmann M
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6169-78. PubMed ID: 15448004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Gly385(388)Arg Polymorphism of the FGFR4 Receptor Regulates Hepatic Lipogenesis Under Healthy Diet.
    Lutz SZ; Hennige AM; Peter A; Kovarova M; Totsikas C; Machann J; Kröber SM; Sperl B; Schleicher E; Schick F; Heni M; Ullrich A; Häring HU; Stefan N
    J Clin Endocrinol Metab; 2019 Jun; 104(6):2041-2053. PubMed ID: 30541128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.